Evidence map›Paper›PMID 33840040›Full record

ArticleHuman cell2021

Proposal for the designation of the natural killer antigens-positive γδ T-cell subset as γδ NKT-cells: nomenclature based on immunoprofile.

Yoshinobu Matsuo, Takahiro Tsujimura, Hans G Drexler

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Human cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Three-Dimensional Modeling ofAntibodies (Basel, Switzerland) · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Yoshinobu MatsuoDivision of Cell Therapy Research, U-Medics, Inc., Matsui 8-1, Utano, Uda, Nara, 633-2221, Japan. matsuo@grandsoul.co.jp.
Takahiro TsujimuraDivision of Cell Therapy Research, U-Medics, Inc., Matsui 8-1, Utano, Uda, Nara, 633-2221, Japan.
Hans G DrexlerTechnical University of Braunschweig, Faculty of Life Sciences, 38126, Braunschweig, Germany.
Nara City Hospital · JPTechnische Universität Braunschweig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer T (NKT)-cells with both T- and NK-cell antigens can be classified into αβ or γδ type according to the TCR gene expression. The WHO classification of lymphoid neoplasms did not further subdivide the above-mentioned NKT-cell malignancies according to the expression of these TCR types. γδ T-cells can be stimulated and expanded by Zoledronic acid, usually carrying Vγ9 Vδ2 TCR and various NK-associated receptors (NKR) such as CD56, CD94, CD158a, CD158b, CD161, etc. In contrast, αβ T-type NKT-cells are positive for Vα24 Vβ11 TCR. NKR positive γδ T-cells have clearly different features than the NKT-cells with Vα24 Vβ11 TCR type, αβ NKT. NKT-cells carrying γδ TCR should be classified and named as γδ NKT-cells to distinguish the cells explicitly from αβ NKT-cells.

Indexed as

Intraepithelial LymphocytesNatural Killer T-CellsReceptors, Antigen, T-Cell, gamma-deltaAntigens, CDGene ExpressionHumansReceptors, Antigen, T-CellAntigens, CDReceptors, Antigen, T-CellReceptors, Antigen, T-Cell, gamma-deltaNKT-cellsαβ NKT-cellsαβ T-cellsγδ NKT-cellsγδ T-cells

Identifiers

PMID33840040
OpenAlexW3154667702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.